TransCode Therapeutics Inc. SEC Form 8-K: Matters Voted on by Security Holders

TransCode Therapeutics, Inc. recently filed a Form 8-K with the Securities and Exchange Commission, detailing matters voted on by security holders. The meeting took place on November 22, 2024, where three important proposals were considered.

First up was the Ratification Proposal, which involved the issuance and sale of securities through a placement agency agreement with ThinkEquity LLC. Stockholders approved this proposal, with 3,659,491 votes for, 1,094,753 against, and 70,611 abstentions. There were also 4,655,205 broker non-votes.

Next was the Reverse Stock Split Proposal, aiming to adjust the company’s outstanding shares of Common Stock. Stockholders gave the green light to this proposal, with 7,271,421 votes for, 2,012,687 against, and 195,952 abstentions. No broker non-votes were recorded for this proposal.

The meeting also saw approval for the Adjournment Proposal, with 7,738,700 votes for, 1,524,796 against, and 216,564 abstentions. Fortunately, no broker non-votes were made. As a result, the need for an adjournment to the Special Meeting was unnecessary, as there were enough votes to approve both the Reverse Stock Split and Ratification Proposals.

These proposals were thoroughly outlined in the company’s Definitive Proxy Statement filed on October 28, 2024. With a total of 17,265,658 shares of Common Stock eligible to vote, the meeting saw a strong presence of 9,480,060 shares either present or represented by valid proxy. All proposals were successfully passed, shaping the future trajectory of TransCode Therapeutics, Inc.